Clinical Trial

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Study acronym: 1 to 3
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-11-11; most recent amendment 2025-12-05.
Status change: Recruiting → Active, Not Recruiting 2025-12-05
Status change: Not Yet Recruiting → Recruiting 2024-03-15
Trial Details
NCT Number NCT05118490
Lead Sponsor The Aurum Institute NPC
Collaborators: Johns Hopkins University
Conditions HIV Seropositivity, Tuberculosis, Household Contact
Enrollment 1,000 participants
Start Date 2023-07-19
Primary Completion 2025-07-11 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-12